Data through close

Net delta positioning extremes

Which liquid chains had the strongest positive and negative delta-weighted positioning on Oct 16, 2026?

Aggregate option-holder delta divided by 100 shares times total open interest. The 25 most positive observations appear first, followed by the 25 most negative. Data through close. Descriptive only, not a recommendation.

At a glance

50 tickers qualified. First five: PBR.A (0.568), CHGG (0.500), INO (0.497), EH (0.486), HLF (0.483).

Net delta positioning extremes as of Oct 16, 2026 close
# Ticker Close Open interest Normalized net delta
1 PBR.A 23.30 216,080 0.568
2 CHGG 0.73 127,423 0.500
3 INO 0.99 108,250 0.497
4 EH 3.61 234,144 0.486
5 HLF 14.60 135,727 0.483
6 NNDM 1.41 135,199 0.480
7 XP 29.23 1,197,182 0.463
8 BNO 67.19 196,348 0.441
9 LAES 1.79 836,814 0.437
10 PAA 25.25 232,633 0.435
11 REI 1.37 135,433 0.433
12 CWH 4.51 106,849 0.424
13 CNC 69.16 207,182 0.421
14 CAN 0.23 148,437 0.415
15 CODI 10.01 258,567 0.404
16 BTG 5.31 527,383 0.400
17 NAK 0.89 224,653 0.397
18 ALT 2.20 178,695 0.396
19 SG 10.04 244,243 0.395
20 PACB 1.73 175,075 0.385
21 IOVA 13.62 407,481 0.372
22 IBRX 9.18 633,602 0.365
23 ETSY 85.14 155,185 0.364
24 KOS 2.78 264,035 0.361
25 DLO 14.67 227,726 0.361
26 ARDX 3.09 201,015 -0.430
27 UAA 4.74 497,093 -0.308
28 KKR 86.21 258,084 -0.257
29 ABR 2.69 165,220 -0.257
30 BX 106.63 456,854 -0.227
31 OWL 8.85 727,148 -0.195
32 COHR 232.90 257,074 -0.183
33 HYG 76.86 9,306,382 -0.179
34 CCJ 81.52 397,150 -0.177
35 KORU 10.64 354,756 -0.171
36 GT 4.29 169,052 -0.168
37 CBRS 127.21 247,678 -0.167
38 RUT 2,721.37 707,213 -0.162
39 SOXX 493.39 496,974 -0.160
40 NLY 18.23 164,006 -0.154
41 AGNC 8.72 693,210 -0.153
42 IWM 270.44 9,513,883 -0.147
43 ASHR 31.12 362,303 -0.146
44 APO 110.78 330,276 -0.146
45 SKHY 136.49 982,154 -0.140
46 KBE 63.62 215,700 -0.136
47 LCID 3.13 835,064 -0.136
48 SMH 539.79 1,492,950 -0.129
49 XLI 167.76 504,946 -0.128
50 XEL 76.31 202,480 -0.127

Screens describe what the data shows after the close. They are not trade recommendations; see the disclaimer and the methodology.